Head-to-head · GSM treatment options
Vaginal CO2/Erbium Laser ($2,400–$3,600 Cash) vs. Local Low-Dose Vaginal Estradiol & DHEA (Intrarosa) for Genitourinary Syndrome of Menopause (GSM)
A vaginal laser series (fractional CO2 such as MonaLisa Touch, or erbium) typically costs $2,400–$3,600 in cash for three sessions, plus yearly maintenance, and no laser is FDA-cleared to treat genitourinary syndrome of menopause (GSM). Low-dose vaginal estradiol is FDA-approved for GSM, has minimal absorption into the bloodstream, and usually costs $10–$45 a month through insurance.
Over three years, that is roughly $3,600–$6,000 for laser versus $500–$2,500 for local estrogen including visits. Vaginal DHEA (Intrarosa) and pelvic floor therapy are FDA-approved or covered alternatives; PRP injections remain experimental.
On this page
01What you are treating: GSM in brief
Genitourinary syndrome of menopause is the umbrella term for changes in the vulva, vagina and lower urinary tract caused by low estrogen: dryness, burning, irritation, pain with sex, reduced lubrication, urgency and recurrent urinary tract infections. It affects a large share of postmenopausal women and, unlike hot flashes, tends to worsen over time without treatment.
Typical diagnosis codes are N95.2 (postmenopausal atrophic vaginitis) and N95.1 (menopausal states), sometimes with N94.10 (dyspareunia) or a recurrent UTI code. Diagnosis is clinical — history and a pelvic exam — and usually needs no special tests.
The treatment ladder most guidelines use
- Step 1 — Non-hormonal care. Regular vaginal moisturizers and lubricants for sex. Helpful for mild symptoms; not a fix for tissue changes.
- Step 2 — FDA-approved local therapy. Low-dose vaginal estradiol (cream, tablet, insert or ring), vaginal DHEA (prasterone, Intrarosa), or oral ospemifene (Osphena) for painful sex.
- Step 3 — Pelvic floor physical therapy when pain, muscle tension or urinary symptoms persist.
- Step 4 — Investigational options such as energy-based devices or PRP, ideally within a study or after FDA-approved options have been tried, with clear consent about limited evidence.
Systemic hormone therapy also helps vaginal symptoms, but many people still need local therapy on top. If you are already on a patch, see our pellets vs patches comparison; local estrogen can be added safely in most cases.
Our GSM and pelvic floor protocol covers the full clinical plan, including microbiome and bladder considerations.
02Head-to-head cost and evidence ledger
The highlighted column is low-dose vaginal estradiol, the guideline-preferred first-line prescription for most women with GSM. Figures are typical 2026 ranges and IntegrativeGyn.com estimates.
| Item | CO2 / erbium laser | Low-dose vaginal estradiol | Vaginal DHEA (Intrarosa) | PRP injection |
|---|---|---|---|---|
| FDA status for GSM | Not cleared for this use | Approved | Approved for menopausal painful sex | Not approved; off-label |
| Regimen | 3 sessions, 4–6 weeks apart, then yearly | Nightly 2 weeks, then 2–3×/week; ring every 3 months | One insert nightly | 1–2 injections, repeat 12–18 months |
| Year-1 cost | $2,400–$3,600 | $120–$540 + visits | $360–$3,000 by coverage | $1,000–$2,000 |
| Years 2–3 | $600–$1,200/yr maintenance | $120–$540/yr | $360–$3,000/yr | $500–$2,000/yr |
| 3-year total | $3,600–$6,000 | $500–$2,500 incl. visits | $1,080–$9,000 | $2,000–$6,000 |
| Insurance | Not covered | Usually covered | Varies; often prior authorization | Not covered |
| Billing | Cash; no dedicated CPT | Pharmacy NDC + 99214 | Pharmacy NDC | Cash |
| Evidence | Mixed; a 2021 sham-controlled trial found no benefit over sham | Strong, decades of data | Randomized trials for painful sex | Small studies only |
Table 1 · Laser and PRP prices are typical cash ranges; prescription prices reflect common generic copays and published list prices; all are IntegrativeGyn.com estimates. Brand products and cash prices vary widely — confirm before you start.
Price the visit side of the estrogen route in the superbill calculator (one intake and one follow-up a year is typical).
03Vaginal laser: what is known and what is not
Fractional CO2 lasers (MonaLisa Touch is the best-known brand) and erbium:YAG lasers make tiny controlled injuries in the vaginal lining intended to stimulate collagen, blood flow and thicker tissue. Clinics typically recommend three treatments four to six weeks apart, then a maintenance session every 12 months.
Regulatory status
These devices are FDA-cleared for general uses such as soft-tissue ablation and coagulation, not specifically for GSM, vaginal dryness or “vaginal rejuvenation.” In 2018 the FDA issued a safety communication warning that energy-based devices had not been established as safe or effective for vaginal rejuvenation or menopause-related symptoms, and noted reports of burns, scarring and pain with sex.
Evidence
Early uncontrolled studies reported improvement. Randomized trials with sham treatment — the type that controls for placebo effect — have been mixed. A 2021 randomized, sham-controlled trial published in JAMA found no significant difference between fractional CO2 laser and sham treatment in vaginal symptoms at 12 months. Some other trials have shown benefit, and research is ongoing. Professional societies, including The Menopause Society, have said more long-term, controlled data are needed before laser can be recommended as a routine treatment.
Who still considers it
- People who cannot or prefer not to use any hormone, including some breast cancer survivors, after discussing non-hormonal options and the evidence.
- People who have tried local estrogen and DHEA without enough benefit.
04Local estrogen, DHEA and other approved options
Low-dose vaginal estradiol
Available as a cream, a 10 mcg vaginal tablet or insert (generic versions of Vagifem), softgel inserts (Imvexxy) and a ring (Estring) replaced every three months. At these doses, absorption into the bloodstream is minimal, and The Menopause Society does not recommend adding a progestogen for endometrial protection with low-dose vaginal estrogen. Most people notice improvement within weeks, with full effect by about three months. It also reduces recurrent urinary tract infections in postmenopausal women.
Historically, vaginal estrogen labels carried the same boxed warning as systemic hormone therapy, which many experts considered misleading for low-dose local products. In late 2025 the FDA announced labeling changes to remove most of that boxed language from menopausal hormone therapy. Check the current label and discuss your history with your clinician.
Vaginal DHEA (prasterone, Intrarosa)
A nightly vaginal insert, FDA-approved for moderate to severe pain with sex due to menopause. DHEA is converted locally into estrogens and androgens. It is an option if you prefer not to use estrogen directly, though coverage varies and cash prices are high.
Ospemifene (Osphena)
An oral, non-estrogen tablet approved for painful sex due to menopause. It acts on estrogen receptors in vaginal tissue, can worsen hot flashes, and carries label warnings similar to other estrogen-acting drugs.
Pelvic floor physical therapy
For pain, muscle guarding and urinary symptoms, pelvic floor PT is often covered by insurance under codes such as 97161–97163 (evaluation), 97140 (manual therapy), 97110 and 97530. Copays commonly run $20–$60 a session.
Breast cancer survivors
Start with non-hormonal care. Low-dose vaginal estrogen may be considered after discussion with your oncology team, particularly if symptoms are severe; the decision depends on your cancer type and treatment.
05PRP injections: the newest and least proven option
Platelet-rich plasma (PRP) is made by drawing your blood, spinning it to concentrate platelets, and injecting it into vaginal or clitoral tissue. It is marketed under names such as the “O-Shot” for dryness, sexual function and urinary leakage.
What the evidence shows
Studies so far are small, often uncontrolled, and use different preparation methods and outcomes, which makes them hard to compare. PRP preparation systems are FDA-cleared for other uses; injecting PRP for vaginal symptoms is off-label. No major guideline recommends it for GSM.
Cost
Typically $1,000–$2,000 per treatment in cash, sometimes bundled with laser at a package price. Repeat treatments every 12–18 months are commonly suggested. Insurance does not cover it, and HSA or FSA eligibility depends on whether it is prescribed to treat a medical condition rather than for cosmetic reasons.
Risks
Generally reported as low — temporary soreness, bruising, swelling — but long-term safety data are limited. Because PRP is your own blood, allergic reactions are unlikely; infection risk depends on technique.
Laser plus PRP packages
Some clinics sell combined “vaginal rejuvenation” packages at $3,000–$5,000. Before buying, ask which part of the package is meant to treat which symptom, what evidence supports each, and whether you can buy one without the other. Packages make it harder to tell what is working.
Clinics offering laser and PRP often also offer pellets; if that is part of your plan, compare it on our pellet network comparison.
07Who should choose which
Start with low-dose vaginal estradiol if…
- You have dryness, irritation, painful sex or recurrent UTIs after menopause.
- You want the most studied, lowest-cost option, usually covered by insurance.
- You are comfortable using a product two to three times a week long term.
Consider vaginal DHEA or ospemifene if…
- Pain with sex is your main symptom and you prefer not to use estrogen directly, or estrogen did not help enough.
- Your plan covers it or you can manage the cash price.
Add pelvic floor PT if…
- You have pain on penetration, muscle tension, urgency or leakage that tissue treatment alone does not fix.
Consider laser only if…
- You cannot use or did not benefit from FDA-approved local therapy, understand that laser is not FDA-cleared for GSM and evidence is mixed, and can budget $3,600–$6,000 over three years.
- You choose an experienced clinician and get the full cost and maintenance plan in writing.
PRP
Best viewed as experimental. If you consider it, ask whether a clinical study is available.
For a full GSM plan including microbiome and bladder care, see our GSM protocol; for recurrent infections, see our recurrent BV and yeast protocol.
This comparison is educational and not individual medical advice; discuss treatment choices with your clinician.
FAQFrequently asked questions
Is MonaLisa Touch FDA-approved for vaginal dryness?
No. Vaginal CO2 and erbium lasers are FDA-cleared for general uses such as soft-tissue ablation, not for genitourinary syndrome of menopause or vaginal dryness. In 2018 the FDA warned that energy-based devices had not been established as safe or effective for vaginal rejuvenation or menopause symptoms. Low-dose vaginal estradiol and vaginal DHEA are FDA-approved treatments for menopause-related vaginal symptoms.
How much does vaginal laser treatment cost?
A typical series of three sessions costs $2,400–$3,600 in cash, followed by maintenance sessions of about $600–$1,200 a year. Over three years that is roughly $3,600–$6,000. Insurance does not cover it. By comparison, generic low-dose vaginal estradiol usually costs $10–$45 a month through insurance, or $500–$2,500 over three years including visits.
Is vaginal estrogen safe long term?
Low-dose vaginal estrogen has minimal absorption into the bloodstream, and The Menopause Society does not recommend adding a progestogen with it. Decades of use support its safety for most women. Any bleeding after menopause still needs evaluation. Breast cancer survivors should discuss it with their oncology team, as the decision depends on cancer type and treatment.
Does the vaginal laser work?
Evidence is mixed. Early uncontrolled studies reported improvement, but a 2021 randomized trial in JAMA comparing fractional CO2 laser with sham treatment found no significant difference in vaginal symptoms at 12 months. Other trials have shown some benefit. Major menopause societies say more long-term controlled data are needed before laser can be recommended routinely.
What is Intrarosa and how is it different from vaginal estrogen?
Intrarosa is prasterone, a DHEA vaginal insert used nightly and FDA-approved for moderate to severe painful sex due to menopause. It is converted in vaginal cells into estrogens and androgens. It is an option if you prefer not to use estrogen directly or if estrogen did not help enough. Insurance coverage varies and often requires prior authorization.
Free · independent · no clinic pays to be recommended
Get matched — or get a second opinion on a quote
Patients: tell us your metro and goal and we route you to clinics whose model fits your budget, or audit a quote you already have. Clinicians: practice-transition, directory and partnership inquiries. We never sell your health information.